The molecular heterogeneity of the pathophysiology of these very rare renal diseases creates a challenge for therapeutic intervention unless a common pathogenic pathway such as C5 activation plays a dominant role, as was the case in Pickering's FH‐deficient mice that were protected by an anti‐C5 antibody. The gene discussed is C5; the disease is kidney disorder.